Additional file 2 of SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

Additional file 2: Table S1. Information of 6009 quantified proteins in renal proteomics. Table S2. Information of 1481 quantified proteins in serum proteomics. Table S3. Information of 501 and 91 DEPs identified in db/db and Empa groups in renal proteomics, respectively. Table S4. Information of 32 EAPs between Empa and db/db groups in kidney. Table S5. Information of 235 and 83 DEPs identified in db/db and Empa groups in serum proteomics, respectively. Table S6. Information of 51 EAPs between Empa and db/db groups in serums. Table S7. Information of 897 quantified metabolites in renal metabolomics. Table S8. Information of 678 quantified metabolites in serum metabolomics. Table S9. Information of 264 identified differentially expressed metabolites between db/db and db/m groups in kidney metabolomics. Table S10. Information of 174 identified differentially expressed metabolites between db/db and db/m groups in serum metabolomics. Table S11. Information of 94 Empa-altered metabolites between Empa and db/db groups in kidney. Table S12. Information of 37 Empa-altered metabolites between Empa and db/db groups in serum.